D-fructofuranose
| Product Name | D-fructofuranose |
|---|---|
| Alternate Names | - Carbohydrates, Carbohydrates of - |
| CAT No. | CS-O-48905 |
| CAS No. | 470-23-5 |
| Category | Carbohydrates |
| Stock | Enquire |
| Mol. Wt. | 180.16 g/mol |
| Mol. For. | C6H12O6 |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | - |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Get an Instant Quote
Related Compounds
GD2Cer d18:1/12:0 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GD3Cer d18:1/18:0-Biotin (Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide-Biotin) | GT2Cer d20:1/18:0 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | Neu5Gca2-3Lea-sp-biotin | GM2Cer d18:1/20:0 (GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GM1bCer d18:1/18:0-Biotin ((Neu5Aca2,3)Galb1,3GalNAcb1,4Galb1,4GlcbCeramide-Biotin) | GM3Cer d18:1/18:0-Biotin ((Neu5Aca2,3)Galb1,4GlcbCeramide-Biotin) | P1(Gala1,4Galb1,4GlcNAcb1,3Galb1,4GlcbR) | GD2Cer d18:1/18:0 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | iGB5Cer d18:1/18:0-Biotin (Galb1,3GalNAcb1,3Gala1,3Galb1,4GlcbCeramide-Biotin) | GD1aCer d20:1/12:0 ((Neu5Aca2,3)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GD2Cer d18:1/24:1 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GM1bCer d20:1/8:0 (Neu5Aca2,3Galb1,3GalNAcb1,4Galb1,4GlcbCeramide) | LacCer d18:1/18:0-Biotin (Galb1,4GlcbCeramide-Biotin) | Epiprogoitrin potassium salt | Carrageenan | GQ3Cer d20:1/8:0 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | Lc3 | Ac3 6AzGlcNAc | Gb5 | GD1aCer d18:1/20:0 ((Neu5Aca2,3)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | L-Rhamnulose | FucGM1Cer d20:1/16:0 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GD3Cer d20:1/8:0 (Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | GM2Cer d18:1/16:0 (GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GT2Cer d18:1/12:0 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GM1bCer d18:1/18:0 (Neu5Aca2,3Galb1,3GalNAcb1,4Galb1,4GlcbCeramide) | Trifucosyllacto-N-hexaose | H-Antigen-Cer d18:1/18:0-Biotin ((Fuca1,2)Galb1,4GlcbCeramide-Biotin) | Galc d18:1/18:0（GalaCeramide） | GD2Cer d18:1/16:0 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | FucGM1sph d20:1 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbSphingolipids) | D-galactosyl-α-1,1' N-palmitoyl-D-erythro-sphingosine | GM2Cer d18:1/8:0 (GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GlcNAcb1, 3Gal | FucGM1Cer d20:1/20:0 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GM2sph d20:1 (GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbSphingolipids) | Galc d18:1/20:0（GalaCeramide） | GM3Cer d20:1/12:0 (Neu5Aca2,3Galb1,4GlcbCeramide) | Lactose PEG-NH2 | GalNAcproN3 | GD1bCer d18:1/18:0 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | Ac3 6AzGalNAc | FucGM1Cer d18:1/24:1 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | Pk(Gala1,4Galb1,4GlcbR) | Sialyl-Lc4 | GD1aCer d20:1/24:1 ((Neu5Aca2,3)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GT3Cer d20:1/16:0 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | Zymosan | GT1cCer d18:1/16:0 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GT2Cer d18:1/8:0 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | ALewis B (ALe b ) | GQ3Cer d20:1/18:0 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | FucGM1Cer d18:1/8:0 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | Gala1, 4Galb1, 4Glc | FucGM1sph d18:1 ((Fuca1,2)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbSphingolipids) | GT3Cer d20:1/24:1 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbCeramide) | GM1bCer d18:1/8:0 (Neu5Aca2,3Galb1,3GalNAcb1,4Galb1,4GlcbCeramide) | GD1aCer d20:1/8:0 ((Neu5Aca2,3)Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | GT2Cer d18:1/24:1 (GalNAcb1,4(Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | GM1bCer d18:1/24:1 (Neu5Aca2,3Galb1,3GalNAcb1,4Galb1,4GlcbCeramide) | GM1aCer d18:1/8:0 (Galb1,3GalNAcb1,4(Neu5Aca2,3)Galb1,4GlcbCeramide) | Neu5Aca2,3Galb1,4(Fuca1,3)(HSO4-6-)GlcNAc | Bortezomib D-mannitol | NeuAca2, 6Galb1, 4GlcNAc | GQ3sph d20:1 (Neu5Aca2,8Neu5Aca2,8Neu5Aca2,8Neu5Aca2,3Galb1,4GlcbSphingolipids) | L-Xylonic acid | Galb1, 4GlcNAcb1, 3Galb1, 4GlcNAcb1, 3Galb1, 4GlcNAc | GD1bCer d20:1/16:0 (Galb1,3GalNAcb1,4(Neu5Aca2,8Neu5Aca2,3)Galb1,4GlcbCeramide) | iGloboH |